Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,796 people get SNY articles and Market Currents by email alert.
Get email alerts on SNY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Aubagio EU Backing Comes With Generic WorriesEP Vantage • Mon, Mar 25 -
-
-
-
-
New Reasons To Be Bullish On SanofiTrading Maven • Tue, Nov 6, 2012 -
-
-
-
-
Sanofi Challenges Novartis For Multiple Sclerosis Market ShareTodd Campbell • Thu, Sep 13, 2012 -
-
-
-
-
-
-
-
-
-
Sanofi Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012 • 1 Comment
-
Sanofi Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Sanofi's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Feb 8, 2012
-
Sanofi's CEO Discusses Q3 2011 Results - Earnings Call TranscriptSat, Nov 5, 2011
-
sanofi-aventis CEO Discusses Q2 2011 Results - Earnings Call TranscriptThu, Jul 28, 2011
-
Sanofi-Aventis CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 28, 2011
-
Genzyme Corporation CEO Discusses Q3 2010 Earnings - Call TranscriptWed, Oct 20, 2010
-
Genzyme Corporation Q2 2010 Earnings Call TranscriptWed, Jul 21, 2010
-
Genzyme Corporation Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Genzyme Corporation Q4 2009 Earnings Call TranscriptWed, Feb 17, 2010
-
Sanofi-Aventis Q4 2009 Earnings Call TranscriptThu, Feb 11, 2010
-
at MarketWatch.com (May 9, 2013)
-
at CNBC.com (May 2, 2013)
-
at CNBC.com (May 2, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at MarketWatch.com (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at MarketWatch.com (Apr 15, 2013)
-
at CNBC.com (Apr 11, 2013)
-
at MarketWatch.com (Apr 2, 2013)
-
at CNBC.com (Mar 26, 2013)
-
at MarketWatch.com (Mar 26, 2013)
-
at MarketWatch.com (Mar 6, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
at MarketWatch.com (Feb 19, 2013)
-
at MarketWatch.com (Feb 11, 2013)
-
at CNBC.com (Feb 11, 2013)
-
at MarketWatch.com (Feb 11, 2013)
-
at CNBC.com (Feb 11, 2013)
-
at MarketWatch.com (Feb 5, 2013)
-
at CNBC.com (Feb 1, 2013)
SNY vs. ETF Alternatives
Company Description
We are a global biotechnology company dedicated to making a major impact on the lives of people with serious diseases. Our broad product and service portfolio is focused on rare genetic disease disorders, renal disease, orthopaedics, cancer, transplant and immune disease, and diagnostic and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, January 3, 5:08 PM Abbott Labs (ABT), Johnson & Johnson (JNJ) and Sanofi (SNY) have all displayed an interest in Warburg Pincus' Bausch & Lomb. Warburg, working through Goldman Sachs (GS), is hoping to get at least $10B for the business and is seeking first-round bids by month’s end. The $10B price tag would be a major coup for Warburg, raking in a 200% return off its $1.7b equity investment. 1 Comment [Healthcare, M&A]
- Tuesday, December 11, 2012, 6:48 PM Goldman Sachs (GS) gets the nod by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division. Warburg is said to be seeking at least $10B for the business. According to reports, Goldman has already contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbott Laboratories (ABT) will be among the other companies contacted. Comment! [Healthcare, M&A]
- Tuesday, October 2, 2012, 3:11 PM Sanofi (SNY) acquires Columbian pharmaceuticals manufacturer Genfar S.A. for an undisclosed sum. Genfar is the second largest generic company in sales and leader in units in Colombia and has a commercial presence in Venezuela, Peru, Ecuador and ten other countries in Latin America. In 2011, its total sales were $133M, with 30% its receipts generated outside Colombia. The deal is expected to close in Q113. Comment! [Global & FX, Healthcare, M&A]
- Tuesday, June 26, 2012, 12:42 PM Five major drug companies are still in the hunt to acquire Amylin (AMLN) as the auction enters its final stage, Reuters reports, with final bids expected to start coming in at the end of the week. The runners and riders are Novartis (NVS), Sanofi (SNY), Bristol Myers (BMY), AstraZenica (AZN) and Merck (MRK). (See also) Comment! [M&A, Healthcare]
- Wednesday, June 13, 2012, 2:34 PM Dendreon (DNDN +19.8%) skyrockets to $7.49/share amidst rumors Sanofi (SNY) is looking to acquire the company for $11/share. Also, Summer Street is starting coverage with a Buy and $18 PT, arguing the Street has "factored in an extremely bear-case scenario" amidst concerns about weaker-than-expected sales of its Provenge prostate cancer drug. It sees Provenge growth and a "turnaround led by new management" driving shares higher. Comment! [Healthcare, On the Move, Quick Ideas, M&A]
- Tuesday, May 15, 2012, 11:52 AM Amylin (AMLN) +6% to $27.19 on reports that it's attracted multiple suitors. Leerink Swann analysts reckon Sanofi (SNY) and Merck (MRK) will emerge as the strongest bidders, and predict a sale price in the mid-$30 a share, although it could go higher if there's a bidding war for the biotech firm. 1 Comment [On the Move, M&A, Healthcare]
- Tuesday, May 15, 2012, 4:27 AM Amylin (AMLN) has apparently attracted interest from potential suitors including Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers (BMY) and Sanofi (SNY), all of which have signed confidentiality agreements on the drugmaker's sale process. Sources say first-round bids are due in the next two weeks. 2 Comments [M&A, Healthcare]
- Monday, April 23, 2012, 2:58 AM Amylin (AMLN) is looking to sell itself, according to sources, and has hired advisers to help solicit possible offers. Several companies, possibly including Sanofi (SNY), are reportedly considering a bid to gain access to Amylin's diabetes portfolio. 1 Comment [Healthcare, M&A, Top Stories]
- Monday, April 2, 2012, 10:48 AM Sanofi (SNY +0.1%) acquires privately-held Newport Laboratories for an undisclosed amount. The pickup gives the French drug maker the ability to expand its cow and pig vaccine business after it stepped back from bidding on Pfizer's animal-health unit. Comment! [Global & FX, M&A]
- Wednesday, March 7, 2012, 10:37 AM Bids are due today for the European part of GlaxoSmithKline's (GSK +0.8%) non-core drugs assets, which could attract £500M ($785M). Those eyeing all or part of the ops include a group comprising Bain Capital and two European partners, as well as Sanofi (SNY), Advent and Avista, Reuters reports. Comment! [Healthcare, M&A]
- Wednesday, January 11, 2012, 6:36 AM Sanofi (SNY) CEO Chris Viehbacher says the company is planning "bolt-on" acquisitions of up to €2B ($2.6B) this year. "All we want to do is continue to look for opportunities, particularly in emerging markets," though the company prefers to look beyond China and India where many peers are focused. Comment! [Healthcare, M&A]
- Monday, July 11, 2011, 4:37 AM Sanofi (SNY) is selling its Dermik dermatology business to Valeant Pharmaceuticals (VRX) for $425M, saying the "divestiture allows us to rationalize our portfolio and improve focus on our core businesses." Premarket: SNY -1.8%. (PR) Comment! [On the Move, Healthcare, M&A]
- Friday, May 6, 2011, 3:14 PM After wrapping its Genzyme purchase, Sanofi-Aventis (SNY +0.5%) drops the "Aventis" from its name in a shareholder vote, and says while it's still on the lookout for emerging-market buys, the pace of acquisitions will slow down to make sure integration goes well. Comment! [Healthcare, M&A]
-
Dividend Sheet
$PVR $LINE and $APL are next Monday's best yielding ex-dividend stocks - http://stks.co/tB0i - 39 shares with 3.98% yield $SNY $CAKE - View all 0 replies
-
- View all 0 replies
-
Chris DeMuth Jr.
MS Drug Lemtrada, owned by Sanofi ($SNY), Effective in Extension Trial: http://seekingalpha.com/a/nhht http://bloom.bg/WOVRiR - View all 12 replies
-
-
Landon R: Reaching for something as I see the price continue to drop. Tempted to go deeper.
-
Dividend Sheet
$CHKR $EFC and $NRF are the best yielding stocks with recent dividend hikes from last week - http://stks.co/gM5z - I like $SNY and $CMCSA - View all 0 replies
-
Dividend Sheet
$NGG $SNY and $CS are the best yielding stocks with buy or better rating from Europe + http://stks.co/eJcR + I like $NVO $BUD and $COV - View all 0 replies
-
Closet Iguana
Healthcare Cloud Computing Market is Expected to Reach USD 6.7B http://adf.ly/HsEQB $SNY $EMR $AMGN $GILD - View all 0 replies
-
Dividend Sheet
$HLF $SNY and $COV are the best yielding stocks from the top 20 buy rated healthcare stocks + http://stks.co/cHAs + I also like $NVO $COO - View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
joe kelly: $40 would be a real good entry for SNY. Be a while for it goes down that far.. -
chopchop0: It's been on a tear the last few months. Wish I had bought more in the 30s. It's popping after hours now to new highs.
-
- View all 2 replies
-
-
LATEST REPLIES
-
Chris DeMuth Jr.
MS Drug Lemtrada, owned by Sanofi ($SNY), Effective in Extension Trial: http://seekingalpha.com/a/nhht http://bloom.bg/WOVRiR - View all 12 replies
-
-
Landon R: Reaching for something as I see the price continue to drop. Tempted to go deeper.
-
- View all 4 replies
-
-
-
- View all 3 replies
-
joe kelly: $40 would be a real good entry for SNY. Be a while for it goes down that far..
-
chopchop0: It's been on a tear the last few months. Wish I had bought more in the 30s. It's popping after hours now to new highs.
-
- View all 2 replies
-
-
-
- View all 3 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 11 replies
-
-
-
- View all 19 replies
-
TruffelPig: Actually, about 50% because I have money markets ongoing that I won't touch. -
-
- View all 1 replies
-
-
- View all 3 replies
-
-
-
- View all 9 replies
-
-
-
- View all 1 replies
-
sstonerm3: Chines, since no one (shorts) is calling you out today, let me be the first. Congratulations on a good day's work.